国产成人精品亚洲777,亚洲乱码日产精品一二三 ,国产99久久亚洲综合精品,欧美疯狂性受XXXXX喷水

Huaota is pleased to announce that the company has received the Clinical Trial Approval in respect of Project HB002.1T issued by the National Medical Products Administration (NMPA) for treatment of advanced solid tumors. HB002.1T is a fusion protein of recombinant human vascular endothelial growth factor (VEGF) receptor and Fc fraction of human IgG targeting VEGF.